Rucaparib's Prostate Cancer Indication Status in 2022-2023
In late 2022, Clovis Oncology announced the voluntary withdrawal of the U.S. Food and Drug Administration (FDA) approval for rucaparib (Rubraca) for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) [1]. This decision followed discussions with the FDA regarding the investigational trial data [1]. The company stated that the withdrawal was effective as of December 2022 [1].
Why Was the Prostate Cancer Indication Withdrawn?
The withdrawal stemmed from the results of the TRITON2 trial, which evaluated rucaparib in patients with BRCA-mutated mCRPC [1][2]. While the trial met its primary endpoint for objective response rate (ORR) in patients with deleterious BRCA mutations, the overall benefit-risk profile for the approved indication was reconsidered by Clovis Oncology in consultation with the FDA [1]. The company indicated that the available data led to the decision to voluntarily withdraw this specific indication [1].
What Does This Mean for Patients?
For patients who were previously prescribed rucaparib for mCRPC, this withdrawal means the drug is no longer FDA-approved for that use [1]. Patients currently on rucaparib for mCRPC were advised to consult with their healthcare providers to discuss alternative treatment options [1]. Clovis Oncology stated it would work with healthcare providers to facilitate any necessary transitions [1].
Is Rucaparib Still Available for Other Uses?
Yes, rucaparib remains FDA-approved for other indications [1][3]. It is still indicated for adult patients with a deleterious BRCA mutation (germline and/or somatic) who have BRCA-mutated metastatic castration-resistant prostate cancer who have received at least one androgen receptor-directed therapy and an approved taxane-based chemotherapy [4]. Rucaparib is also approved for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and in whom the cancer is associated with a deleterious BRCA mutation (germline and/or somatic), and who have responded to a platinum-containing chemotherapy [4].
What Are the Next Steps for Rucaparib Research?
Clovis Oncology indicated that it would continue to work with investigators and regulatory authorities on ongoing clinical trials involving rucaparib, including those investigating its use in earlier lines of therapy for ovarian cancer [1]. The company also stated its commitment to exploring rucaparib's potential in other tumor types [1].
Where Can I Find More Information on Drug Patents and Approvals?
Information on drug approvals, withdrawals, and patent exclusivity can be found on DrugPatentWatch.com [5]. This resource provides details on the regulatory status and patent landscape of various medications.
Sources
1. DrugPatentWatch.com
2. Clovis Oncology Press Release, December 2022
3. FDA Approved Drug Products
4. Rubraca Prescribing Information
5. DrugPatentWatch.com